Sophia Genetics

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today announced that Ross Muken, previously Chief Financial Officer (“CFO”) and Chief Operating Officer (“COO”), has been promoted to company President, effective November 5, 2024. George Cardoza has been appointed as the company’s new CFO....Show more

SOPHiA GENETICS Promotes Ross Muken to President and Appoints George Cardoza as Chief Financial Officer

2

“Our collaboration with AstraZeneca represents a major step forward in personalized oncology. Non-small cell lung cancer remains one of the most challenging cancers to treat due to its complex biology and the late stage at which it is often diagnosed,” said Jurgi Camblong, Ph.D., Co-founder and CEO of SOPHiA GENETICS. “This study harnesses the power of multimodal data and advanced AI to identify which patients are most likely to benefit from specific therapies. By tailoring treatment strategies based on a patient’s unique multimodal profile, we aim to improve outcomes and offer new hope to those battling this difficult disease.”...Show more

SOPHiA GENETICS Presents Ground-Breaking Multimodal Research on AI-Driven Patient Stratification at ESMO 2024

0

Under the new generation of SOPHiA DDM™, genomic, radiomic, and multimodal analytics capabilities will be offered in a single, integrated workspace. Customers benefit from the three analytics modules by selecting applications that best suit their needs: Genomics: Ingests genomics FASTQ and VCF data to efficiently call, annotate, and pre-classify oncogenic or pathogenic variants. Radiomics: Processes data from various imaging modalities (e.g., CT scans, PET-CT, MRI), segments anatomical areas of interest, and extracts radiomic features for further analysis. Multimodal: Aggregates data from the radiomics and genomics modules, along with processed clinical, biological, and histological data, to train and verify predictive models at the individual patient level....Show more

SOPHiA GENETICS Unveils New Generation of the SOPHiA DDM™ Platform at Morgan Stanley Healthcare Conference 2024

0

“At SOPHiA GENETICS, certification of our SOPHiA DDM™ Platform under IVDR builds on our track record of offering a broad set of CE-IVD applications and giving our customers confidence in knowing they are using a cutting-edge, compliant Platform for their analysis needs,” said Daan Van Well, LL.M., M.B.A., Chief Legal and Compliance Officer SOPHiA GENETICS. “This was a top priority for our team to ensure a seamless transition for our current CE-IVD customers so they can continue to use the SOPHiA DDM™ Platform to support diagnosis and treatment decisions for patients facing cancer.” ...Show more